News

Inspire Pharmaceuticals, a biopharmaceutical company, has initiated a Phase II program with AzaSite 1% to pursue a potential indication for the treatment of blepharitis, an ocular disease characterized

Ocimum Biosolutions, a genomics services company, has launched a new microarray-based test, for research use only, for the latest version of the H1N1 flu. The company has reported

Pulmatrix has reported that it will initiate a randomized, double-blind, placebo-controlled Phase Ib/IIa clinical trial of its novel inhaled therapy, PUR003, to demonstrate its effectiveness, safety and tolerability

Astellas Pharma Canada has reported encouraging results from a Canadian study which showed that patients with overactive bladder treated with solifenacin reported significantly lower incidence and severity of

The company has reported total revenues of $519.97 million for the first quarter of 2009 compared to $443.22 million for the first quarter of 2008. Frank Baldino Jr,

The first force-sensing ablation catheter developed worldwide, TactiCath gives physicians a real-time, objective measure of contact force during the catheter ablation procedure, said Endosense. The CE Mark allows

As part of the agreement, Ergomed will advance the oral formulation of tasidotin, developed by Genzyme, into clinical trials. In an earlier Phase II clinical trial sponsored by

By promoting the development, coordination and sharing of research resources and expertise, these awards expand research opportunities and increase the number of competitive investigators in 23 eligible states

Ranbaxy Pharmaceuticals, a wholly owned subsidiary of Ranbaxy Laboratories, has reported that it is conducting a voluntary recall of all lots of Nitrofurantoin capsules, USP 100mg currently on